December 2025 decisions news release
The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, December 08) published advice on five medicines.
Givinostat (Duvyzat®) was accepted as a treatment for Duchenne muscular dystrophy in patients aged six years and older. Duchenne muscular dystrophy is a rare genetic disorder that causes muscle weakness and loss of function.
Maralixibat (Livmarli®) was accepted for the treatment of cholestatic pruritis (intense itch due to a build-up of bile) caused by Alagille syndrome in patients aged two months and older.
Amivantamab (Rybrevant®), used together with chemotherapy, was accepted for the treatment of adults with advanced non-small cell lung cancer.
Delgocitinib (Anzupgo®) was accepted for the treatment of moderate to severe chronic hand eczema in adults. Chronic hand eczema is a long-term condition that causes the skin of the hands to be itchy, red and dry.
An ultra-orphan initial assessment report has been published for leniolisib (Joenja®), a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), in patients aged 12 years and older. APDS is a very rare genetic condition that affects the immune system. The Scottish Government will confirm when leniolisib is available for prescribing and further evidence will be gathered. Following this SMC will review it and decide on routine availability in NHSScotland.
SMC Chair Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHSScotland.
“We heard powerful testimony from patient groups about the impact of Duchenne muscular dystrophy on patients and families. Givinostat will provide a new treatment option for this devastating condition.
“The intense itch associated with Alagille syndrome can affect all aspects of a person’s life. We know the acceptance of maralixibat will be welcomed.
“Amivantamab, used together with chemotherapy, offers the potential to delay the progression of disease in certain adults with advanced non-small cell lung cancer.
“Delgocitinib is a new cream for people with chronic hand eczema that works in a different way than existing treatments.”